相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Carla Casulo et al.
BLOOD (2022)
Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Franck Morschhauser et al.
BLOOD (2021)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2021)
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
Sophie Snyder et al.
ADVANCES IN THERAPY (2021)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
Connie L. Batlevi et al.
BLOOD CANCER JOURNAL (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
How do I sequence therapy for follicular lymphoma?
Gilles Salles
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Caron Jacobson et al.
BLOOD (2020)
Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
Sarit E. Assouline et al.
BLOOD (2020)
AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2 ) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS
J. Leonard et al.
HEMATOLOGICAL ONCOLOGY (2019)
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
Alfredo Rivas-Delgado et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J. Schuster et al.
BLOOD (2019)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Martin Dreyling et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Unmet needs in the first-line treatment of follicular lymphoma
C. Casulo et al.
ANNALS OF ONCOLOGY (2017)
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn et al.
BLOOD (2014)
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
Daryl Tan et al.
BLOOD (2013)
分享论文
